ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 246

Adult Autoinflammatory Disease Frequency and Our Diagnostic Experience in an Adult Autoinflammatory Clinic

Qingping Yao1, Felicitas Lacbawan2 and Jianbo Li1, 1Cleveland Clinic, Cleveland, OH, 2Molecular Genetics Pathology, Cleveland Clinic, Cleveland, OH

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Autoinflammatory Disease, Familial Mediterranean fever, fever and nod-like receptor (NLR), Traps

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Autoinflammatory diseases (AIDs), aka, periodic fever syndromes include monogenic diseases, such as familial Mediterranean fever (FMF), cryopyrin-associated periodic disease (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), and hyper IgD periodic syndrome (HIDS), and polygenic disease like NOD2-associated AID (NAID). A diagnosis of these diseases is clinically challenging in adults, and it often relies on genetic testing. Our aim is to study the disease frequency and report our diagnostic experience.

Methods:

A total of 266 adult patients with clinical phenotypes at presentation were referred due to a concern for AIDs to our Adult AID Clinic at Cleveland Clinic between November 2009 and February 2015. All patients were genotyped for NOD2mutations or periodic fever syndrome panel in commercially available genetic testing centers, depending on a clinical suspicion of an individual disease. The case definition included patients of 17 years of age and older and the definite diagnosis of each disease was deemed to be present if both clinical phenotypes and genetic confirmation were met. The patient electronic medical records were examined for demographic, clinical and genetic data. The frequency of positive genetic testing was calculated to estimate the concordance between the clinical diagnosis and genetic confirmation.

Results:

Of 266 patients, 79 (26.4%) were diagnostic of AIDs, including 54 cases of NAID, 13 FMF, 6 TRAPS, 5 CAPS and 1 HIDS. Of the 143 patients at risk for NAID, 37.8% were confirmed to have NAID, with 85% specificity of the NOD2 genetic testing. Thirteen (44.8%) of 29 patients clinically suspicious for FMF had positive genetic testing. Six (9%) of 66 patients had positive testing for TRAPS. Five (21.7%) of 23 patients had positive testing for CAPS. Only one out of 5 patients was tested positive for HIDS. The demographic and genetic data of these patients with definite AIDs are summarized (Table 1). The frequencies of the genetic tests among these patients were higher (all Ps <0.001) as compared to the literature controls (Table 2). These data demonstrated that the AIDs diagnosed in our Clinic included NAID, FMF, TRAPS, CAPS and HIDS in a descending order. The concordance between the clinical suspicion and positive genetic testing results was higher for FMF and NAID, but it was extremely low for TRAPS. Since these AIDs share overlapping clinical phenotypes and are indistinguishable frequently, the most commonly encountered diseases, NAID and FMF, should be preferably considered. Given the extreme rarity of TRAPS and HIDS in adults and very low genetic detection rate, we suggest caution be exercised to order the genetic testing for these two disorders. 

Conclusion:

Our study demonstrates that NAID and FMF are relatively common in adults. TRAPS and HIDS are extremely rare and the concordance between clinical suspicion and positive genetic testing is very low for both diseases. To be cost-effective, an ordering of genetic testing for AUIDs should highly consider both the disease frequency and stringent phenotypes, and a consultation with experts should be encouraged.


Disclosure: Q. Yao, None; F. Lacbawan, None; J. Li, None.

To cite this abstract in AMA style:

Yao Q, Lacbawan F, Li J. Adult Autoinflammatory Disease Frequency and Our Diagnostic Experience in an Adult Autoinflammatory Clinic [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/adult-autoinflammatory-disease-frequency-and-our-diagnostic-experience-in-an-adult-autoinflammatory-clinic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adult-autoinflammatory-disease-frequency-and-our-diagnostic-experience-in-an-adult-autoinflammatory-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology